Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study

被引：7
|
作者：
Mascarenhas, John
Higgins, Brian
Anders, Doreen
Burbury, Kate
El-Galaly, Tarec Christoffer
Gerds, Aaron T.
Gupta, Vikas
Kovic, Bruno
Maffioli, Margherita
Mesa, Ruben
Palmer, Jeanne M.
Passamonti, Francesco
Rambaldi, Alessandro
Ross, David M.
Vannucchi, Alessandro M.
Yacoub, Abdulraheem
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-135868
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly
    Kirito, Keita
    Suzuki, Kenshi
    Miyamura, Koichi
    Takeuchi, Masahiro
    Handa, Hiroshi
    Okamoto, Shinichiro
    Gadbaw, Brian
    Yamauchi, Kyosuke
    Amagasaki, Taro
    Ito, Kazuo
    Hino, Masayuki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (02) : 173 - 184
  • [22] Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly
    Keita Kirito
    Kenshi Suzuki
    Koichi Miyamura
    Masahiro Takeuchi
    Hiroshi Handa
    Shinichiro Okamoto
    Brian Gadbaw
    Kyosuke Yamauchi
    Taro Amagasaki
    Kazuo Ito
    Masayuki Hino
    International Journal of Hematology, 2018, 107 : 173 - 184
  • [23] Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib With Best Available Therapy in Hydroxyurea-Resistant/Intolerant Patients With Polycythemia Vera
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 4 - 6
  • [24] Differences in Clinical Outcomes Between Hydroxyurea-Resistant and-Intolerant Polycythemia Vera Patients
    Lee, Sung-Eun
    Hong, Junshik
    Bang, Soo-Mee
    Park, Jinny
    Choi, Chul Won
    Bae, Sung Hwa
    Kim, Min Kyoung
    Yoon, Seug Yun
    Kim, Sung-Yong
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2024, 39 (03)
  • [25] Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera
    Verstovsek, Srdan
    Passamonti, Francesco
    Rambaldi, Alessandro
    Barosi, Giovanni
    Rosen, Peter J.
    He, Shui
    Contel, Nancy
    Mookerjee, Bijoyesh
    Rumi, Elisa
    Gattoni, Elisabetta
    Pieri, Lisa
    Cazzola, Mario
    Kantarjian, Hagop M.
    Barbui, Tiziano
    Vannucchi, Alessandro M.
    BLOOD, 2012, 120 (21)
  • [26] Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available
    Foltz, Lynda
    Pica, Gian-Matteo
    Zerazhi, Hacene
    Van Droogenbroeck, Jan
    Visanica, Sorin
    de la Fuente, Enrique Baez
    Leber, Brian
    de Almeida, Antonio Medina
    Ranta, Dana
    Cartes, Mauricio Reyes
    Kiladjian, Jean-Jacques
    Chrit, Linda
    Yin, Zhaoyu
    Morando, Juliane
    Devos, Timothy
    BLOOD, 2018, 132
  • [27] Characteristics and Clinical Outcomes in Patients (Pts) With Polycythemia Vera (PV) Receiving Ruxolitinib (RUX) After Hydroxyurea HU): A Longitudinal Analysis From REVEAL
    Gerds, Aaron T.
    Grunwald, Michael R.
    Oh, Stephen T.
    Braunstein, Evan
    Xue, Zhenyi
    Bhatt, Valkal
    Yu, Jingbo
    Mesa, Ruben
    BLOOD, 2022, 140 : 6810 - 6812
  • [28] A randomized phase II, open-label trial of orally administered SAR302503 in patients with polycythemia vera (PV) or essential thrombocythemia (ET) who are resistant or intolerant to hydroxyurea
    Tefferi, Ayalew
    Cortes, Jorge E.
    Hochhaus, Andreas
    Kiladjian, Jean-Jacques
    Mesa, Ruben A.
    Pardanani, Animesh Dev
    Lebedinsky, Claudia
    Neumann, Frank
    Hsu, Karl
    Vannucchi, Alessandro M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] Real-World Dosing Patterns of Ruxolitinib in Patients with Polycythemia Vera Who are Resistant to or Intolerant of Hydroxyurea
    Altomare, Ivy
    Nguyen, Anna
    Parasuraman, Shreekant
    Paranagama, Dilan
    Kish, Jonathan K.
    Lord, Kevin
    Colucci, Philomena
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S326 - S327
  • [30] Real-World Dosing Patterns of Ruxolitinib in Patients With Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea
    Altomare, Ivy
    Parasuraman, Shreekant
    Paranagama, Dilan
    Kish, Jonathan
    Lord, Kevin
    Yu, Jingbo
    Colucci, Philomena
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : E915 - E921
12345